WAVE Life Sciences (WVE) Projected to Post Earnings on Tuesday

Key Points

• WAVE Life Sciences will report Q1 2026 results before the market opens on April 28 at 8:30 AM ET; analysts expect EPS -$0.34 and $8.45M in revenue.
• The company last missed EPS on Feb. 26 (reported -$0.30 vs. estimate -$0.28) despite a revenue beat ($17.25M), remains unprofitable with a large negative net margin, and analysts model roughly -$1 EPS for the fiscal year.
• Insiders were net sellers (52,373 shares sold last quarter; insiders own 23.98%), while Wall Street’s consensus is a Moderate Buy with an average target of $30.63 versus the current share price near $7.31.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Tuesday, April 28th. Analysts expect WAVE Life Sciences to post earnings of ($0.34) per share and revenue of $8.4510 million for the quarter. Interested persons may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, April 28, 2026 at 8:30 AM ET.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.02). WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%. The company had revenue of $17.25 million for the quarter, compared to analyst estimates of $15.68 million. On average, analysts expect WAVE Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

WAVE Life Sciences Stock Down 0.9%

Shares of WAVE Life Sciences stock opened at $7.31 on Friday. WAVE Life Sciences has a fifty-two week low of $5.02 and a fifty-two week high of $21.73. The firm has a market cap of $1.38 billion, a PE ratio of -5.99 and a beta of -1.32. The business's fifty day moving average is $10.60 and its two-hundred day moving average is $11.23.

Insider Transactions at WAVE Life Sciences

In related news, insider Chandra Vargeese sold 3,228 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $43,416.60. Following the transaction, the insider directly owned 408,246 shares of the company's stock, valued at approximately $5,490,908.70. This trade represents a 0.78% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Paul Bolno sold 10,480 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $140,956.00. Following the completion of the transaction, the chief executive officer directly owned 275,520 shares in the company, valued at $3,705,744. This trade represents a 3.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 52,373 shares of company stock valued at $757,527. Corporate insiders own 23.98% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in WVE. Smartleaf Asset Management LLC raised its position in shares of WAVE Life Sciences by 645.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company's stock worth $38,000 after buying an additional 1,942 shares during the period. Russell Investments Group Ltd. raised its position in shares of WAVE Life Sciences by 1,441.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company's stock worth $73,000 after buying an additional 9,284 shares during the period. Tower Research Capital LLC TRC raised its position in shares of WAVE Life Sciences by 44.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,658 shares of the company's stock worth $76,000 after buying an additional 3,609 shares during the period. Prudential Financial Inc. purchased a new position in shares of WAVE Life Sciences in the 2nd quarter worth $80,000. Finally, CIBC Bancorp USA Inc. purchased a new position in shares of WAVE Life Sciences in the 3rd quarter worth $87,000. 89.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Wells Fargo & Company reduced their price target on WAVE Life Sciences from $27.00 to $13.00 and set an "overweight" rating on the stock in a research note on Friday, March 27th. Mizuho increased their price target on WAVE Life Sciences from $22.00 to $27.00 and gave the stock an "outperform" rating in a research note on Wednesday, March 25th. Cantor Fitzgerald increased their price target on WAVE Life Sciences from $34.00 to $41.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. HC Wainwright reduced their price target on WAVE Life Sciences from $30.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, April 14th. Finally, Wedbush increased their price target on WAVE Life Sciences from $33.00 to $35.00 and gave the stock an "outperform" rating in a research note on Friday, March 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $30.63.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company's pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington's disease, as well as early-stage cardiovascular and liver indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.